Condition: Type 2 Diabetes · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.
This description comes directly from the study's public registry record.
Bi Yan · 86+13655176388 · biyan@nju.edu.cn
Ge Zhi Juan · 86+18061758651 · gzjyunduan@126.com
Always discuss trial participation with your own doctor first.
| Xinyang Central Hospital | Xinyang, Henan, China | Recruiting |
| Affiliated Drum Tower Hospital, Medical School of Nanjing University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07023172